|
|
|
 Analyses
All Central and Eastern Europe (CEE) countries allow advertising of OTC products to the public but under some conditions. In Poland, medicinal products may be advertised to the general public if they are not Rx or included ... more
»
2012-02-22
Amid the usual flurry of foreign direct investment (FDI), merger and acquisition (M&A) activity and government drug sector cost-containment activity in the last quarter of 2011, serious questions arose about ... more
»
2012-02-16
As drug prices in the Czech Republic are among the lowest in the European Union, drugs often leave the country through parallel exports. According to the Czech State Institute for Drug Control (SUKL) estimates, the ... more
»
2012-02-07
The majority of the Central and Eastern Europe (CEE) countries have just expressed their plans to implement e-prescription or implemented pilot e-prescription schemes, but none of them has a fully operational e-prescription ... more
»
2012-02-07
Central Europe Pharma News talks to Andrej Pardo, Country Head Czech Republic & Slovakia at Sandoz and the new Chairman of the Association of Pharmaceutical Companies (CAFF) representing generic companies in ... more
»
2012-02-02
The updated version of the Ministry of the Treasury’s privatisation plan for 2009-2011 envisaged the following companies from the pharmaceutical and healthcare sectors to be privatised in the period in question: ... more
»
2012-01-25
In May 2011, the Hungarian government decided to increase the 12% tax payable by pharmaceutical manufacturers on revenues from reimbursed drugs to 20% from 1 July 2011 onwards.
In June 2011, the Hungarian Parliament ... more
»
2012-01-23
The year 2011 saw numerous legislative changes shaking up the Hungarian pharmaceutical market. Pfizer warned that the additional fiscal burden brought about by the new regulations would force innovative pharmaceutical ... more
»
2012-01-23
The online sales of OTC drugs take place in all the Central and Eastern Europe (CEE) countries, but the legal framework in the individual countries imposes specific limitations in this respect. Hence, online sales ... more
»
2012-01-17
Penta, a private-equity group conducting its business on the markets of Central Europe, for 10 last years has been largely active in the healthcare segment in the region, in particular in Slovakia, the Czech Republic ... more
»
2012-01-10
Robust growth and substantial investments are expected in the Romania private healthcare sector. Although the privatisation of hospitals is not imminent, a great deal is happening in the private segment, where several ... more
»
2012-01-10
2011 experienced numerous mergers and acquisitions (M&A) attempts on the pharmaceutical, private healthcare and medical devices markets in Central and Eastern Europe (CEE). The significant consolidation processes took place particularly ... more
»
2012-01-10
The new Reimbursement Act in Poland which is take effect from January 2012 envisages a total ban on sales promotions of reimbursed medicines and on any forms of advertising by pharmacies. However Poland is not the only ... more
»
2011-12-14
This year Hungarian companies Gedeon Richter and Egis improved their positions in the EU’s “2011 Industrial R&D Investment Scoreboard”. This was due to the increased outlays on R&D in 2010. ... more
»
2011-12-14
The 2010-2011 period has seen intensified activity of two Polish companies operating on the domestic in vitro diagnostics market: BioMaxima and PZ Cormay. Both companies have been engaged in the acquisition processes, ... more
»
2011-12-06
Low salary (six to ten times lower than those of doctors in other European countries according to Istvan Eger, president of the Hungarian Medical Chamber) is a serious problem in Hungary. That is one of the reasons why ... more
»
2011-11-30
Despite the continued pursuit of vigorous cost containment-focused drug sector reform, merger and acquisition activity and foreign direct investment (FDI) remain a major feature of Central and Eastern European (CEE) ... more
»
2011-11-17
Today, pharmaceutical companies are trying to focus resources on core activities and to reduce infrastructure expenses which are not directly related to core functions. They therefore relocate business processes from ... more
»
2011-11-02
In 2010 OTC product pharmacy sales in Central and Eastern Europe (CEE) were worth €10.7bn, a 13% year on year increase in euro. Between 2011 and 2013 the market should develop by around 9% on average per annum, according ... more
»
2011-10-19
see more analytical articles »
|
|
|
Copyright © 2012 PMR. All rights reserved.
PMR is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern Europe as well as other emerging markets. PMR key areas of operation include
business publications (through PMR Publications),
consultancy (through PMR Consulting) and
market research (through PMR Research). Being present on the market since 1995, employing highly skilled staff, offering high international standards in projects and publications, providing one of most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.
PMR Online Access
Browse and search in our archive »